Johanna Schleutker
 PhD, Professor of Medical Genetics

Cancer, Infections and Immunity

johanna.schleutker@utu.fi

+358 29 450 2726

+358 50 443 7237

Kiinamyllynkatu 10

Turku


ORCID-tunnistehttps://orcid.org/0000-0002-1863-0305

Genetic Cancer Predisposition




Asiantuntijuusalueet
Cancer genetics; hereditary cancer; genomics; human genetics

Biografia

Johanna Schleutker got her PhD in 1995 in University of Turku, Faculty of Medicine.The topic of her doctoral thesis was "Linkage disequilibrium is Salla disease; positioning of the sialic acid transport defect". She then moved to University of Tampere, and did her post doc in 1996-1998 in the Cancer Genetics research group of Professor Olli Kallioniemi. Her career continued in the US where she spent the years of 1999-2000 working as a research associate at the National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. During the NIH years, she studied genetics of familial prostate cancer in the group of Dr. Jeffrey M.Trent. After her return to Finland, Schleutker started her own research group in 2001 at the Insitute of Medical Technology, University of Tampere, and has ever since focused her studies on genetics and genetic susceptibility of prostate and breast cancer. Schleutker got a professorship in University of Tampere in 2008. In 2011 she started as a professor of medical genetics in University of Turku.



Tutkimus

The Schleutker group "Genetic Predisposition to Cancer" is studying both breast and prostate cancer genetics, the main emphasis being on prostate cancer. Of all cancers, prostate cancer (PrCa) has been reported as one of the most heritable diseases: genetic factors have been estimated to account for 57% of the risk. The goal is to identify and characterize predisposing genes and variants, especially those affecting aggressive outcome, including treatment responses to therapies. Further, the aim is to develop tools for prognostic purposes, i.e. prognostic biomarkers. The group has identified many significant genomic risk regions, candidate genes and variants, which have been then further profiled and characterized by functional studies. The group has produced (by 2021) 12 PhD degrees and published over 190 original, peer-reviewed articles in international journals.



Opetus

Genetics, cancer genetics, hereditary cancer, genomics, molecular biology.



Julkaisut
  
null
  
null
  
5/22
  
null
  
null
  

  • Genomic prediction of alcohol-related morbidity and mortality  (2020)  
    • Translational Psychiatry
     Kiiskinen T, Mars NJ, Palviainen T, Koskela J, Ramo JT, Ripatti P, Ruotsalainen S, Palotie A, Madden PAF, Rose RJ, Kaprio J, Salomaa V, Makela P, Havulinna AS, Ripatti S
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Inherited DNA repair gene mutations in men with lethal prostate cancer  (2020)  
    • Genes
     Tommi Rantapero, Tiina Wahlfors, Anna Kähler, Christina Hultman, Johan Lindberg, Teuvo L. J. Tammela, Matti Nykter, Johanna Schleutker, Fredrik Wiklund
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells  (2020)  
    • Nature
     Erik L. Bao, Satish K. Nandakumar, Xiaotian Liao, Alexander G. Bick, Juha Karjalainen, Marcin Tabaka, Olga I. Gan, Aki S. Havulinna, Tuomo T. J. Kiiskinen, Caleb A. Lareau, Aitzkoa L. de Lapuente Portilla, Bo Li, Connor Emdin, Veryan Codd, Christopher P. Nelson, Christopher J. Walker, Claire Churchhouse, Albert de la Chapelle, Daryl E. Klein, Björn Nilsson, Peter W. F. Wilson, Kelly Cho, Saiju Pyarajan, J. Michael Gaziano, Nilesh J. Samani, Aviv Regev, Aarno Palotie, Benjamin M. Neale, John E. Dick, Pradeep Natarajan, Christopher J. O’Donnell, Mark J. Daly, Michael Milyavsky, Sekar Kathiresan, Vijay G. Sankaran; FinnGen; 23andMe Research Team
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers  (2020)  
    • Nature Medicine
     Mars Nina, Koskela Jukka T., Ripatti Pietari, Kiiskinen Tuomo T. J., Havulinna Aki S., Lindbohm Joni V., Ahola-Olli Ari, Kurki Mitja, Karjalainen Juha, Palta Priit, Neale Benjamin M., Daly Mark, Salomaa Veikko, Palotie Aarno, Widén Elisabeth, Ripatti Samuli; FinnGen
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Polygenic Hyperlipidemias and Coronary Artery Disease Risk  (2020)  
    • Circulation: Genomic and Precision Medicine
     Ripatti P, Ramo JT, Mars NJ, Fu Y, Lin JK, Soderlund S, Benner C, Surakka I, Kiiskinen T, Havulinna AS, Palta P, Freimer NB, Widen E, Salomaa V, Tukiainen T, Pirinen M, Palotie A, Taskinen MR, Ripatti S; and on behalf of FinnGen
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Prostate cancer risk prediction using a polygenic risk score  (2020)  
    • Scientific Reports
     Csilla Sipeky, Kirsi M. Talala, Teuvo L. J. Tammela, Kimmo Taari, Anssi Auvinen & Johanna Schleutker
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma  (2020)  
    • PLoS Genetics
     Tanigawa Yosuke, Wainberg Michael, Karjalainen Juha, Kiiskinen Tuomo, Venkataraman Guhan, Lemmelä Susanna, Turunen Joni A, Graham Robert R, Havulinna Aki S, Perola Markus, Palotie Aarno, Daly Mark J, Rivas Manuel A; FinnGen
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • ShAn: An easy-to-use tool for interactive and integrated variant annotation  (2020)  
    • PLoS ONE
     Rathinakannan VS, Schukov HP, Heron S, Schleutker J, Sipeky C
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor  (2020)  
    • Cancers
     Brandao A, Paulo P, Maia S, Pinheiro M, Peixoto A, Cardoso M, Silva MP, Santos C, Eeles RA, Kote-Jarai Z, Muir K, Schleutker J, Wang Y, Pashayan N, Batra J, Gronberg H, Neal DE, Nordestgaard BG, Tangen CM, Southey MC, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sorensen KD, Cybulski C, Grindedal EM, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Vega A, Kogevinas M, Wiklund F, Penney KL, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Roobol MJ, Teixeira MR; Profile Study Steering Comm; PRACTICAL Consortium
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • The effect of sample size on polygenic hazard models for prostate cancer  (2020)   Karunamuni RA, Huynh-Le MP, Fan CC, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Gronberg H, Wiklund F, Aly M, Schleutker J, Sipeky C, Tammela TLJ, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Ben Schottker, Holleczek B, Park JY, Sellers TA, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Mills IG, Andreassen OA, Dale AM, Seibert TM, Seibert TM; & The PRACTICAL Consortium
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )



Last updated on